2.1
Dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) is indicated for 'the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation'.
2 Information about dabrafenib plus trametinib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for dabrafenib.
Price
2.3
Dabrafenib costs £1,400 per 28‑pack of 75 mg capsules and trametinib costs £4,800 per 30‑pack of 2 mg tablets (excluding VAT; BNF online accessed February 2023).
2.4
The company has a commercial arrangement. This makes dabrafenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.